In support of a protective role for PRC2 in breast cancer, we found that mutations in PRC2 core components are associated with a poor prognosis and documented several mutations in EZH2 and PRC2 core component SUZ12 in breast cancer metastases. This evidence concerns the gene EZH2 and breast carcinoma.